Fortrea Establishes Industry Partnership with Veeva and Advarra to Streamline Patient and Site Clinical Trial Experience
09 Gennaio 2024 - 10:22PM
Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract
research organization (CRO), today announced an industry
partnership with founding members Veeva Systems Inc., a leading
provider of industry cloud solutions for the global life sciences
industry, and Advarra, a leading provider of clinical research
technology for clinical research investigator sites and sponsors,
to deliver an integrated patient- and site-centric solution that
streamlines the clinical trial experience.
In an industry faced with complex challenges to clinical trial
execution, Fortrea is establishing an alliance of industry
partners—beginning with founding members, Veeva and Advarra—to
tackle some of these challenges head-on. Many sites are burdened by
administrative operations that have multiple, complex technologies
with limited interoperability. This impacts their ability to focus
on what matters most—the patients—and improving their recruitment
and experience participating in clinical studies.
Fortrea, Veeva and Advarra are partnering to offer a seamless,
unified technology solution that integrates best-in-class
technologies and leverages Fortrea’s process expertise. This will
help ease the administrative burden for patients and sites and
increase the accessibility of clinical trials for the public.
“We heard from our Site Advisory Board that the multitude of
technologies used on a study is one of their greatest challenges,”
said Fortrea Chief Operating Officer and President of Clinical
Services Mark Morais. “Working with industry-leading partners and
founding members, Veeva and Advarra, we’re taking action to remove
complexities so we can address the pain points of sites and
patients and make a difference. We are leveraging our unique
vantage point in the industry that enables us to layer our
expertise over the tech and data ecosystems from best-in-class
partners—adding to our alliance as we go—to dramatically simplify
the experience for patients, sites and sponsors.”
For sites, the partnership is set to deliver:
- a cloud-based, simplified sign-on experience for Fortrea-run
studies
- access to study technologies through a single dashboard
- a unified environment with a single repository for study
documents and records
For patients, the solution is being designed to offer:
- easy-to-access, step-by-step, visit-by-visit support and
education throughout a patient’s trial journey
- a simplified user experience through a single platform
- self-referral functionality to search and find studies in their
disease area of interest
- ongoing patient support and education via an online portal or
mobile app
- a simplified mobile and web application for consenting and
responding to outcome surveys
“Veeva is helping to advance clinical trials with connected
applications that reduce the burden of participating for patients,
streamline execution for research sites and increase transparency
for sponsors,” said Jim Reilly, vice president, Veeva Development
Cloud Strategy. “Extending our partnership with Fortrea to deliver
Veeva Clinical Platform applications will meet the unique needs of
patients, sites and sponsors while significantly improving study
data quality and collaboration with sites.”
“Advarra’s mission is to break the silos that impede clinical
research, so we are excited to provide our Longboat solution and
IRB services as part of this innovative and collaborative
partnership aimed at reducing site and patient burden,” said Elisa
Cascade, chief product officer at Advarra. “By leveraging our
Longboat solution, Fortrea will deliver a reimagined clinical
research experience that will improve both protocol compliance and
site and patient engagement throughout the clinical trial
process.”
Learn more about how Fortrea is driving healthcare innovation
throughout the world at Fortrea.com. For more information on the
technology platforms, visit Veeva Clinical Platform and Advarra
Longboat.
About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical
development and patient access solutions to the life sciences
industry. We partner with emerging and large biopharmaceutical,
medical device and diagnostic companies to drive healthcare
innovation that accelerates life changing therapies to patients in
need. Fortrea provides phase I-IV clinical trial management,
clinical pharmacology, differentiated technology-enabled trial
solutions and post-approval services. Fortrea’s solutions leverage
three decades of experience spanning more than 20 therapeutic
areas, a passion for scientific rigor, exceptional insights and a
strong investigator site network. Our talented and diverse team of
about 19,000 people working in more than 90 countries is scaled to
deliver focused and agile solutions to customers globally. Learn
more about how Fortrea is becoming a transformative force from
pipeline to patient at Fortrea.com and follow us on LinkedIn and X
(formerly Twitter) @Fortrea.
Fortrea Contacts:Fortrea Media: Galen Wilson –
703-298-0802, media@fortrea.com Fortrea Media: Kate Dillon –
646-818-9115, kdillon@prosek.com
Grafico Azioni Fortrea (NASDAQ:FTRE)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Fortrea (NASDAQ:FTRE)
Storico
Da Dic 2023 a Dic 2024